Alteogen Inc. · KRX:196170
Alteogen — Investor Presentation (April 2026)
16 slides from Alteogen's investor presentation, Apr 9, 2026
Slide 1: Alteogen Investor Presentation
Alteogen Investor Presentation 2026. 4.9. @ ALTEOGEN
Slide 2: NexP, NexMab, Hybrozyme
NexP NexMab Hybrozyme Long-Acting Biobetter Antibody-Drug Conjugate Novel Human Hyaluronidase Ultra-Long-Acting Biobetter
Slide 3: Alteogen's Robust Hyaluronidase Package
=== Alteogen’s Robust Hyaluronidase Package ot Va ALT-B4 AHS] HA FOS VA A|Sz} | DoH Segs, gde, ws, AAs Sa APSStE|O] US FERC, Wes, JHA] S SSHAE |Z! ASE|O SC ALS Vt MSD, GSK, AstraZeneca, Daiichi Sankyo, Biogen, Intas, Top 10 Pharma S 77H BEE AHA 2to/A @ALTEOGEN SAME ALT-B4S SoH Al? O/M-SSLICHA] ALT-B
Slide 4: Licensing Agreements for Subcutaneous Formulation Conversion
———= DOpEAL(SC) MSt MS HWS FS SASS Sst SEH Aol MA Alo SH Ala SAA, AVHAAAS Alar S 21 Al SAO SC ASLS HES EN| Licensing Agreements for Subcutaneous (SC) Formulation Conversion © Nov. 29 © Jan. 7 * Nov. 8 © Jan. 20 _ Non-exclusive license Exclusive license Exclusive license Exclusive license _ agreement
Slide 5: 2026 ALT-B4 License Agreement with Biogen
——= 202614 spo/H=z}ol = Hay DHELAY SEA Solberg SAZ| sal Se ILS Biogen ®p,: Biogen (Unit : USD) IN Upfront Milestones us Fl Ok 20H $20M + $10M 8 4B Al) Up to $549M HEO| OA 274 SS SCMES! Alot $579M + Royalty @ ALTEOGEN ( >) - ASAE Biogen Inc. AlSFUS: SE O4l ALT-B4S BSF Biogen Hto| Sos 274 SSI UlSp>EAt
Slide 6: ADC Paradigm Shift
o|SFELI|CAS SEt ADC 22S Paradigm Shift ALT-B4 + ADC 21% S24 24 > Therapeutic window SHS SéH C] BS2!= ADC 7H 7s © ADC $S4t blu e ADCSC Sa A IV CHa] SPANO PK BAI, ABBAS BI MAPS Zh HS ALT-B4S} ZBtet SC Io] oFa144 BOI SC ADC PK experiment (Payload) ADC SC SC ADC experiment 3B (Minipig Yucatan) RASAUISE
Slide 7: 2019 2020 2021 2022 2023 2024 2025 2026E 2027E 2028E 2029E 2030E 2031E
⚫ ⚫ 15,000 10,000 5,000 0 2019 2020 2021 2022 2023 2024 2025 2026E 2027E 2028E 2029E 2030E 2031E
Slide 8: Growth strategy through 2030
——= JJESCI SCE ATOR SSHAES SCAMS test 0/0174 Enhertu, Imfinzi, Jemperli S$ ABO2 | New assets & platforms 2026 - 2030 - Open collaborations B= TEA Sty - Next-generation platforms, Alzt sc AZ Sch including the ultra-long-acting Increasing revenue through platform the commercialization of multiple prod
Slide 9: ALT-P1 growth hormone data
⚫ ⚫ 12 AHV (cm) 8 4 0 ALT-P1 0.6 mpk ALT-P1 0.8 mpk Genotropin
Slide 10: Ultra-Long-Acting Platform: Once-Monthly Obesity Treatment
A once-monthly A/3 O@ H|PtA| eA] ALANA] SAF HO|AY Sry O! SOkASe Stat eres Novel Once-Monthly Treatment (M5) @ Results from animal studies (PD data) Vehicle ase —ee8e Weight Loss (%) vs Time (Day) PK 28 SoH SHAS AEA tsa Sol PD BH SoH HAH As Sat MB)at SAS FHO| HS AA Stel 59 SE S rebound CHa} H| SH Bl]
Slide 11: External Collaboration
== External Collaboration ” 1 I AFOAd J/HEO| X}AE Mz Beez g chy zy BEY OOP Arysy Oe AES et ste 2 0|‘r41|0|44(Open Innovation) “218712 U(\nlicense) - 32H2| ApH] BAS 7| es Het Sew /qatoi7t wet - 1-ABH (Mga) 3 xEOL - 2EZO| 347} HHO] DA ey HE CMC / HIS / BS ALAS - lz 3! UFO| mato! JER] 47} SE veseneescm
Slide 12: ALTS-OP01: Potentially Best-in-Class Fusion Protein for wAMD
=== ALTS-OPO1: Potentially Best-in-Class Fusion Protein for wAMD VEGF 7|#t Szt at Ang-2 7|#t Get SSIS SALOl MOSS SHH A] aH] © rely G8 Bhs (wAMD) / te3 BtS(DME) © ALTS-OPO17|Z AE] CHS AHA, Sapo! Saba A] Sze APB SI ASA] St Se Seisixp Aaa Multi-functional ALTS-OP01 wAMD ‘2414 35 ‘31A(E) $22.88 O17] ALT
Slide 13: ALTS-OP01: Potentially Best-in-Class Fusion Protein for wAMD
=== ALTS-OPO1: Potentially Best-in-Class Fusion Protein for wAMD AB|At SE QAwpO2eAA State 0% S QA EM|& MOF HEE S ... 2026 AL FDA IND AIS SE @ Invivo CNV Model Study @ ALTS-OPO1 v. Vabysmo E}2! B2E/A3& Yat Anti-Ang2 Ang-2 Ang-1* VEGF (On-Target) (Off-Target) VABYSMO 1X 1X 80 Aflibercept : : : ALTS-OP
Slide 14: Alteogen
ALTEOGEN www.alteogen.com
Slide 15: Appendix
=== Appendix Healthy eye Ang-1 > Ang-2; VEGF VY Choriocapillaris (fenestrated endothelium) Retinal capillary Source: Joussen AM et al, Eye (2021) 36:1305-1316 @ALTEOGEN Neovascular AMD Ang-2 > Ang-1; Hypoxia; VEGF 7 Anti-Ang-2 Anti-VEGF-A Neovascularisation, Macrophage infiltration — RPE damage, vas
Slide 16: Appendix: Approved ADCs
=== Appendix: Approved ADCs Drug Gemtuzumab ozogamicin Brentuximab vedotin Trastuzumab emtansine Inotuzumab ozogamicin Moxetumomab pasudotox-tdfk Polatuzumab vedotin Enfortumab vedotin Trastuzumab deruxtecan Sacituzumab govitecan Belantamab mafodotin Cetuximab sarotalocan Loncastuximab tesirine Disi